Care of patients with systemic immunoglobulin light chain (AL) amyloidosis has undergone transformative changes, leading to marked, steady progress in outcomes for patients over the past four decades.
In a recent study published in the journal Nature, researchers investigate whether pairs of unrelated B-cells of naive, unswitched, memory and plasmablast phenotypes that have similar heavy chains ...
Light chain amyloidosis is not cancer, but cancer drugs are this rare disease’s standard of care. The patient need for new treatment options has sparked R&D efforts at biotech and big pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results